Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics

Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q3 2026

Management view

• “Vertex achieved another quarter of excellent commercial results and pipeline advancement.” (CEO, President & Director Reshma Kewalramani) She highlighted that “Third quarter total revenue grew 12% year-on-year,” with growth “balanced coming from both the U.S. and international from CF and from our 2 more recently launched medicines, CASGEVY and JOURNAVX as well as a contribution from PALSONIFY for the month of September post close of the Crinetics acquisition.” (CEO Kewalramani)

• Management formalized endocrine as a commercial pillar post-deal: “Rare endocrine is now our fourth commercial pillar.” (CEO Kewalramani) She also tied near-term focus to renal execution: “With the PDUFA date later this month for povetacicept in immunoglobulin A nephropathy… we plan to soon establish our fifth in renal.” (CEO Kewalramani)

• Leadership transition was explicitly framed: “Given the January 1 transition by Charlie to the COO role solely, please note that this is his last quarterly earnings call and as successor, Jonathan Poole, our current SVP of Finance, will join us for our Q4 2026 call in February.” (SVP Investor Relations Susie Lisa)

• Commercial momentum across recent launches was quantified: “Through the first 9 months of the year, our ongoing launches of ALYFTREK, CASGEVY and JOURNAVX have generated over $2 billion in revenue, led by over $1.7 billion in ALYFTREK sales and more than $350 million in combined CASGEVY and JOURNAVX sales.” (Executive VP & Chief Commercial Officer Duncan J. McKechnie)

• CF positioning and next-gen cadence were sharpened: “We see ALYFTREK as the most effective medicine approved for CF.” (CEO Kewalramani) On VX-828, she said, “In short, these are excellent results,” while adding, “given the very high bar set by ALYFTREK, we intend to wait for all the data from the next gen 3.0 family of molecules before determining next steps.” (CEO Kewalramani)

• Portfolio prioritization in type 1 diabetes shifted toward VX-017: “After careful analysis, we have chosen to prioritize acceleration of VX-017 as our lead program.” (CEO Kewalramani) She added, “We have already begun dosing patients with VX-017 in a Phase I/II study,” with a goal “of moving to pivotal development next year.” (CEO Kewalramani)

• CFO framing emphasized both performance and cost/financing impacts: “Vertex delivered strong third quarter results with total revenue growth of 12% year-over-year.” (Executive VP, COO & CFO Charles Wagner) He added that Q3 operating expenses “include approximately $60 million of Crinetics operating and integration-related expenses in September,” and that the company incurred “approximately $50 million in nonoperating costs associated with the Crinetics transaction financing.” (Executive VP Wagner)

Outlook

• “For total revenue guidance, we are raising our prior range of $13.1 billion to $13.2 billion to a revised range of $13.15 billion to $13.25 billion.” (Executive VP Wagner) He attributed the revision to Crinetics: “we expect [Crinetics] to contribute $40 million to $50 million to full year 2026 revenue.” (Executive VP Wagner)

• Non-CF revenue expectations were reiterated with additional endocrine contribution: “We continue to expect more than $500 million in revenue from CASGEVY and JOURNAVX with additional contribution from 4 months of PALSONIFY.” (Executive VP Wagner)

• Expense and profitability cadence changed with the acquisition close: “we are revising our prior combined non-GAAP operating expense guidance of $5.65 billion to $5.75 billion to a revised estimate of approximately $6 billion,” with the increase “attributable to the inclusion of approximately $250 million of Crinetics operating expenses and integration-related costs.” (Executive VP Wagner)

• Financing headwinds were quantified in guidance language: “For the full year of 2026, we expect total nonoperating costs of approximately $105 million related to the financing of Crinetics,” and “interest income is projected to be approximately $60 million lower than it otherwise would have been.” (Executive VP Wagner)

Financial results

• “Third quarter 2026 non-GAAP net income was $1.21 billion and third quarter 2026 non-GAAP earnings per share were $4.76.” (Executive VP Wagner)

• Margin and spend reflected mix and acquisition accounting: “On a non-GAAP basis, third quarter gross margin was 85.6%.” (Executive VP Wagner) He said GAAP gross margin “includes intangible asset and inventory step-up amortization resulting from the purchase accounting for the Crinetics acquisition.” (Executive VP Wagner)

• The quarter showed step-up in commercial investment tied to launches: “Non-GAAP SG&A expense was $556 million… Nearly 80% of the incremental spend was to enhance our commercial capabilities,” with key drivers “Pove in renal, and JOURNAVX and then PALSONIFY.” (Executive VP Wagner)

• Capital and leverage posture post-acquisition was detailed: “We ended the quarter with approximately $9.8 billion in cash and investments,” and “we raised $4.5 billion of term loans… currently bearing interest at approximately 4.8%.” (Executive VP Wagner)

Q&A

• Cory Kasimov, Evercore ISI: Asked about a citizen petition and whether IgG monitoring/dose-hold rules in RAINIER would carry into practice; CEO Kewalramani responded, “there are about 200 or so of these… every year… This one… was anonymous,” adding, “we studied over 500 people… measured every 4 weeks,” and “There are no opportunistic infections… [SAEs] are balanced… exactly 0.5% in Pove and 0.5% in the placebo group.” (CEO Kewalramani)

• Jessica Fye, JPMorgan: Asked what would represent a “win” for AMPLITUDE on proteinuria/eGFR; CEO Kewalramani said, “A win would be a statistically significant result on the GFR slope,” and “our agreement with the FDA on what would be acceptable for accelerated approval is GFR.” (CEO Kewalramani)

• Salveen Richter, Goldman Sachs: Asked about Pove manufacturing comfort and confidence into AMPLITUDE separation at interim; CEO Kewalramani said, “We’ve been with the same manufacturer all through Phase III,” and on inaxaplin, “substantial reductions in proteinuria… have timing again been linked to improvements in GFR,” adding that FDA “are going to be comfortable accepting 1-year GFR differences.” (CEO Kewalramani)

• Geoffrey Meacham, Citigroup: Asked about competitive relevance of 2-year eGFR in IgAN and what “a win” in DPN trials would look like; CEO Kewalramani said, “we are fully on track to complete enrollment,” and “a win would be beating placebo,” while on IgAN data maturity, “we’re going to go to the 2-year eGFR full completion… because our ambition is to launch Pove around the globe.” (CEO Kewalramani) CCO McKechnie added that nephrologists’ conviction has strengthened and said Pove has “best-in-class potential.” (Executive VP McKechnie)

• Evan Seigerman, BMO: Asked about PSP duration and the bridge from prescription growth to revenue; CCO McKechnie said Vertex has made “the strategic decision to keep the PSP program switched on,” adding, “We will sunset it by the middle of 2027,” and “gross to net… [to] stabilize… in the range of 50% to 60%.” (Executive VP McKechnie)

• Brian Abrahams, RBC: Asked about Pove launch uptake dynamics and ALYFTREK conversion trajectory; CCO McKechnie said ALYFTREK growth has been driven by “new reimbursement agreements… outside the U.S.” and “new rare mutation indications.” (Executive VP McKechnie) On IgAN opportunity, he referenced “about 3,000 patients on medicine” for competitors and said that “leaves us with 163,000 yet to go.” (Executive VP McKechnie)

• Michael Yee, UBS: Asked about PARASOL discussions and eGFR math/read-through from IgAN; CEO Kewalramani said, “the FDA and our agreement is indeed with GFR,” and on mechanism, “it matters not only that you get the proteinuria down. It matters how you get the proteinuria down.” (CEO Kewalramani)

• Tazeen Ahmad, BofA: Asked how VX-828 compares to expectations and what residual CF unmet need remains; CEO Kewalramani said “the range of outcomes covers our expectations,” and that Vertex will choose among “3 medicines in this NG 3.0 family,” adding, “we are almost superimposable onto the Gaussian distribution of sweat chloride of normal people.” (CEO Kewalramani)

• Akash Tewari, Jefferies: Asked why Vertex committed to 2-year eGFR continuation now and how crossover/dropouts are handled; CEO Kewalramani said, “our ambition is global filings,” and “there are clear rules in the statistical analysis plan… We’re simply going to follow the rules.” (CEO Kewalramani)

• Terence Flynn, Morgan Stanley: Asked whether AMPLIFIED modest-proteinuria response was driven by FSGS subset; CEO Kewalramani said, “The majority of patients did not have FSGS,” and “the response… was not driven by an FSGS cohort.” (CEO Kewalramani)

• Mohit Bansal, Wells Fargo: Asked about continuous manufacturing risk for Pove; CEO Kewalramani replied, “the agency has been involved,” and “yes, I feel good about the filing.” (CEO Kewalramani)

Sentiment analysis

• Analysts: Slightly negative to neutral tone concentrated around regulatory/manufacturing risk and durability/endpoint rigor, shown in questions on “citizen petition,” “continuous manufacturing,” and what constitutes “a win” on eGFR in AMPLITUDE and DPN. (Analyst questions cited above)

• Management: Slightly positive and confident tone, repeatedly emphasizing readiness and conviction, including “we are 100% ready” for the PDUFA date (Executive VP McKechnie) and “we’re really looking forward to our PDUFA date” (CEO Kewalramani), while also using boundary-setting language on specifics: “I won’t go through all of them in excruciating detail.” (CEO Kewalramani)

• Versus last quarter: Q3 tone reflected execution after closing Crinetics (versus Q2’s “definitive agreement to acquire Crinetics Pharmaceuticals”), with more scrutiny from analysts on manufacturing/regulatory mechanics as Pove approached the PDUFA date. (CEO Kewalramani, prior-quarter and current-quarter remarks)

Quarter-over-quarter comparison

• Acquisition status moved from pending to closed, changing both pillars language and financial guidance framing: Q2 described “the definitive agreement to acquire Crinetics Pharmaceuticals” (CEO Kewalramani), while Q3 said, “With the Crinetics acquisition now closed, PALSONIFY… is our eighth commercialized medicine.” (CEO Kewalramani)

• Guidance was raised and explicitly included Crinetics in Q3, while Q2 guidance excluded it: Q2 said, “today’s guidance does not yet reflect the pending Crinetics acquisition.” (Executive VP Wagner) Q3 said revenue guidance was raised to “$13.15 billion to $13.25 billion” and expects “$40 million to $50 million” from Crinetics. (Executive VP Wagner)

• Expense outlook stepped up in Q3 to reflect integration/launch build, versus Q2 reiteration: Q2 operating expense guidance remained “$5.65 billion to $5.75 billion” (Executive VP Wagner), while Q3 revised to “approximately $6 billion.” (Executive VP Wagner)

• Analyst focus shifted from launch preparation to near-approval risk controls: Q2 questions emphasized endpoints and competitive positioning; Q3 concentrated on Pove label/monitoring, manufacturing, and uptake mechanics alongside PSP/gross-to-net timing. (Analyst Q&A excerpts across both calls)

Risks and concerns

• Manufacturing and regulatory scrutiny around Pove surfaced repeatedly, with management addressing both label and CMC concerns: “there’s also a review of the CMC manufacturing package” (CEO Kewalramani) and “the agency has been involved.” (CEO Kewalramani)

• Revenue conversion risk in pain was explicitly linked to the PSP and contracting dynamics: JOURNAVX Q3 revenue “reflects continued high gross to net with the patient support savings program remaining on,” and Medicare Part D contracting created “a onetime reset in net revenue.” (Executive VP McKechnie)

• Financing drag from the Crinetics transaction was embedded in results and guidance: “approximately $50 million in nonoperating costs,” lower interest income from “lower cash balances,” and term loans “bearing interest at approximately 4.8%.” (Executive VP Wagner)

Final takeaway

Vertex management emphasized balanced growth across CF and newer launches, formally integrated Crinetics into guidance, and positioned PALSONIFY as the foundation of a new rare endocrine pillar while preparing for a near-term IgAN decision with povetacicept. Executives highlighted a higher 2026 revenue range of $13.15 billion to $13.25 billion with added Crinetics contribution, alongside a higher operating expense outlook to support pipeline and launch infrastructure. In Q&A, investors pressed on Pove label/manufacturing risk and on renal trial endpoints, while management repeatedly anchored accelerated approval paths to eGFR and described launch readiness, PSP strategy in pain through mid-2027, and continued CF lifecycle planning under a “very high bar set by ALYFTREK.”

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.